Summary of Panlong Pharmaceutical Conference Call Company Overview - **Company Name**: Panlong Pharmaceutical - **Established**: 1997, listed on Shenzhen Stock Exchange in 2017 - **Core Product**: Panlong Seven Tablets, a patented Class A medical insurance product - **Production Capacity**: 25 production lines certified by the new national GMP, with supporting inspection and research facilities [3][4] Industry and Market Position - **Market Coverage**: Active in 30 provinces, with over 650 commercial partners and access to more than 5,000 medical institutions and 50,000 grassroots medical units [2][5] - **Future Expansion**: Plans to expand into southern markets [2][5] - **Growth Drivers**: Significant growth in traditional Chinese medicine (TCM) sales, particularly in TCM slices, with over 4,440 varieties and 25 fine powder approvals [8][5] Financial Projections - **2026 Revenue Target**: Estimated at 1.8 billion yuan, focusing on TCM slices, innovative drugs, and hospital preparations [3][30] - **Panlong Seven Tablets Sales Forecast**: Expected to reach 650 million yuan in 2026, with a potential 30% increase if included in the essential drug list [2][20][29] Product Development and Innovation - **New Product Launches**: Plans to introduce 3-4 best-selling new products in the next 3-5 years, including Panlong Seven Gel Patch and Loxoprofen Sodium [3][15][23] - **Current Product Line**: Includes TCM slices, TCM formula granules, and innovative drugs, with a focus on classic formulations and chemical preparations [3][15] Competitive Advantages - **Unique Selling Proposition**: Panlong Seven Tablets consist of 29 herbal ingredients, including 17 rare medicinal materials, with proven efficacy and safety, recommended by clinical guidelines [18][19] - **Supply Chain Stability**: Raw material costs are stable due to self-sufficient production bases and partnerships for cultivation [12][19] Marketing and Sales Strategy - **Sales Channels**: Traditional hospital sales are increasing, with a shift from 80:20 to 70:30 in favor of hospital sales [26][28] - **Online Sales**: Managed by subsidiary Panlong Yunkuang Technology, with plans for online promotions through partnerships with media and internet companies [16][26] Challenges and Risks - **Market Competition**: The TCM formula granules market is competitive, but the company is optimistic about its unique production capabilities in Shaanxi province [13][14] - **Regulatory Changes**: Potential changes in the essential drug directory could impact market dynamics and sales strategies [20][22] Future Outlook - **Long-term Strategy**: Focus on expanding market share in TCM slices and innovative drugs, while also developing the health product segment [17][30] - **Production Capacity Assurance**: Prepared for increased demand with production line arrangements to ensure capacity [29] Additional Notes - **Collaboration Projects**: Ongoing collaboration with Qianchuan Pharmaceutical for establishing a Chinese herbal medicine base, with updates expected in future reports [11] - **Profit Margins**: Specific gross margin data for TCM slices not disclosed, but expected to be competitive with industry standards [10]

Product Strategy - The company focuses on a development strategy termed "one body, two wings, three depths," emphasizing orthopedic chronic diseases as the main body and integrating brand commercialization and traditional Chinese medicine innovation [3] - A diverse product matrix is being constructed, including over 100 varieties across 12 functional categories, with a strong emphasis on the proprietary product "Panlong Seven Tablets" [3][6] - The company is committed to continuous innovation in the health sector, with a focus on both existing drug business and long-term health trends [3] AI and Innovation - The company is actively engaging in AI-driven innovation in pharmaceuticals, collaborating with research institutions to build a comprehensive database for traditional Chinese medicine [4] - Plans include significant investment in regional medicinal data initiatives, particularly focusing on the "Seven Medicines" unique to Shaanxi [4] Marketing and Distribution - The company has established a dual-channel marketing network covering over 20,000 grassroots medical institutions and more than 30,000 retail pharmacies [5] - A multi-faceted marketing model integrates product promotion, academic innovation, and brand building to enhance product recognition and clinical acceptance [5] - The inventory management system ensures stable channel inventory and smooth turnover for core products [5] Product Development - The core product "Panlong Seven Gel Patch" is in clinical trials and aims to complement the oral product "Panlong Seven Tablets" for a synergistic effect in orthopedic treatments [6] - The company is advancing multiple research projects, including innovative traditional Chinese medicines and high-end formulations, to establish a robust product pipeline for sustainable growth [6]

Group 1: Company Overview and Strategy - The company focuses on innovation in pharmaceuticals, adhering to a strategic framework of "one body, two wings, and three depths" to enhance its core competitiveness [2][4] - It has established a complete industrial chain covering standardized planting, production, research and development, sales, and logistics [3][4] Group 2: Research and Development Progress - In 2025, the company accelerated its R&D efforts, with key products like the improved traditional Chinese medicine "Panlong Qining Gel Patch" receiving clinical trial approval [3] - The company aims to achieve a "21355" target for major product cultivation, developing a diverse product ecosystem that includes both oral and external applications [3] Group 3: Main Products and Market Position - The leading product, "Panlong Qipian," has a market share of 7.73% in the traditional Chinese medicine market for musculoskeletal diseases [6] - "Panlong Qipian" is recognized as a unique patented product and has been included in multiple national clinical guidelines and expert consensus [5][6] Group 4: Marketing and Sales Strategy - The company has built a comprehensive marketing network across 30 provincial administrative regions, collaborating with over 650 commercial partners [6] - It has expanded its reach to over 30,000 retail pharmacies and 20,000 grassroots medical units, creating a dual-channel sales strategy [6] - The digital marketing strategy has improved user lifecycle management efficiency by 40% and marketing response speed by 60% [6]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its product, Panlong Qining Gel Patch, for the treatment of knee osteoarthritis [2] Group 1 - The approval includes the issuance of a "Drug Clinical Trial Approval Notice" [2] - The clinical trial will focus on the efficacy of the gel patch in treating knee osteoarthritis [2]

Core Viewpoint - The company, Panlong Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of its Panlong Qiniang Gel Patch for knee osteoarthritis [1] Company Summary - Panlong Qiniang Gel Patch is developed from Panlong Qiyao Wine, consisting of 30 medicinal ingredients including Panlong Qiyao and Zhuangjindan [1] - The new gel patch formulation offers significant advantages over the original form in terms of convenience, speed of action, and target user demographics [1] - The primary therapeutic functions of the product include promoting blood circulation, dispelling wind and dampness, and reducing swelling and pain, specifically for knee osteoarthritis with symptoms of Qi stagnation and blood stasis [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its product, Panlong Qining Gel Patch, for the treatment of knee osteoarthritis [1] Company Summary - Panlong Qining Gel Patch is an improved formulation derived from Panlong Qiyao Wine, consisting of 30 medicinal ingredients including Panlong Qiyao and Zhuangjindan [1] - The new gel patch formulation offers significant advantages over the original form in terms of ease of use, speed of effect, and target user demographics [1] - The primary therapeutic functions of the product include promoting blood circulation, dispelling wind and dampness, and reducing swelling and pain, specifically for knee osteoarthritis characterized by Qi stagnation and blood stasis [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its product, Panlong Qining Gel Patch, for the treatment of knee osteoarthritis [1] Company Summary - Panlong Qining Gel Patch is an improved formulation derived from Panlong Qiyao Wine, consisting of 30 medicinal ingredients including Panlong Qiyao and Zhuangjindan [1] - The new gel patch formulation offers significant advantages over the original form in terms of ease of use, speed of action, and target user demographics [1] - The primary therapeutic functions of the product include promoting blood circulation, dispelling wind and dampness, and reducing swelling and pain, specifically for knee osteoarthritis characterized by Qi stagnation and blood stasis [1]

Core Viewpoint - The company, Panlong Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of its Panlong Qiniang Gel Patch for knee osteoarthritis [1] Company Summary - Panlong Qiniang Gel Patch is developed from Panlong Qiyao Wine, consisting of 30 medicinal ingredients including Panlong Qiyao and Zhuangjindan [1] - The new gel patch formulation offers significant advantages over the original form in terms of convenience, speed of action, and target user demographics [1] - The primary therapeutic functions of the product include promoting blood circulation, dispelling wind and dampness, and reducing swelling and pain, specifically for knee osteoarthritis with symptoms of Qi stagnation and blood stasis [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its Panlong Qiniang Gel Patch for knee osteoarthritis [1] Group 1: Product Development - The Panlong Qiniang Gel Patch is derived from the improved Panlong Qijiu and consists of a formula made from 30 medicinal ingredients including Panlong QI and Zhuangjindan [1] - The primary functions of the product are to invigorate blood circulation, dispel wind and dampness, and reduce swelling and pain, specifically targeting knee osteoarthritis characterized by Qi stagnation and blood stasis [1]

Financial Performance - In the first three quarters of 2025, the company achieved revenue of 841 million CNY, a year-on-year increase of 17.37% [2] - The net profit attributable to shareholders reached 89.81 million CNY, with a slight year-on-year growth of 0.26% [2] - For Q3 2025, revenue was 267 million CNY, showing a year-on-year growth of 2.24%, while net profit was 29.67 million CNY, remaining stable compared to the same period last year [2] Market Coverage - The company has established coverage in over 5,000 grade A medical institutions and penetrated more than 30,000 retail pharmacies and 20,000 grassroots medical units [3] - A network of over 650 commercial partners has been established across 30 provincial-level administrative regions, enhancing sales channels [3] Product Strategy - The company is focusing on the "Health China 2030" strategy, integrating R&D, production, and quality control to enhance product offerings [3] - A comprehensive marketing management system has been developed, employing a differentiated strategy for various products and markets [3] - The company is actively expanding its presence in the "Internet + Medicine" sector, leveraging digital marketing platforms and partnerships with major e-commerce platforms [3] Inventory Management - Channel inventory from commercial companies to hospitals is maintained at under one month, ensuring smooth turnover of core product inventories [4] Herbal Formula Granules - The herbal formula granules business is a key growth area, with 411 product varieties successfully registered and approved by the National Medical Products Administration [5] - The company is progressing with the listing of 111 products in nine provinces and is working on a second batch of 100 products [5] Research and Development - The company is advancing the development of the "Panlong Seven" gel patch, a strategic product for treating rheumatic bone diseases, which has recently received clinical approval [6] - The R&D pipeline includes other innovative drugs and chemical generics, with ongoing clinical trials for various products [6]